Sagimet Biosciences (SGMT) Assets Average (2023 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Assets Average of $112.1 million for Q1 2026, down 26.82% year-over-year from $153.2 million in Q1 2025, and down 8.43% quarter-over-quarter from $122.4 million in Q4 2025.
Sagimet Biosciences (SGMT) Assets Average (2023 - 2026) Analysis & Trends
Sagimet Biosciences' Assets Average history runs 4 years deep, the most recent figure standing at $112.1 million for Q1 2026.
- In Q1 2026, Assets Average fell 26.82% year-over-year to $112.1 million; the TTM figure through Mar 2026 stood at $112.1 million (down 26.82% YoY), while the FY2025 annual figure was $138.4 million, up 7.69% from the prior year.
- Assets Average for Q1 2026 stood at $112.1 million, down from $122.4 million in the prior quarter.
- The five-year high for Assets Average was $191.8 million in Q2 2024, with the low at $62.2 million in Q3 2023.
- The 4-year median for Assets Average is $141.8 million (2025), against an average of $137.4 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average jumped 192.39% in 2024, then declined 26.93% in 2025.
- Sagimet Biosciences' Assets Average stood at $99.8 million in 2023, then soared by 67.82% to $167.5 million in 2024, then declined by 26.91% to $122.4 million in 2025, then dropped by 8.43% to $112.1 million in 2026.
- Business Quant data shows SGMT's Assets Average at $112.1 million in Q1 2026, $122.4 million in Q4 2025, and $132.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 185.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 185.59 Mn |
| Mar 31, 2026 | 112.12 Mn |
| Dec 31, 2025 | 122.44 Mn |
| Sep 30, 2025 | 132.90 Mn |
| Jun 30, 2025 | 141.79 Mn |
| Mar 31, 2025 | 153.22 Mn |
| Dec 31, 2024 | 167.52 Mn |
| Sep 30, 2024 | 181.90 Mn |
| Jun 30, 2024 | 191.77 Mn |
| Mar 31, 2024 | 145.62 Mn |
| Dec 31, 2023 | 99.82 Mn |
| Sep 30, 2023 | 62.21 Mn |